Key result
Oral anticoagulation is preferred for AF cardioembolism while antiplatelet therapy is favored for other etiologies.
Why the study?
What is the optimal antithrombotic therapy for stroke prevention based on stroke etiology?
What is the optimal antithrombotic therapy for stroke prevention based on stroke etiology?
The choice of antithrombotic therapy for stroke prevention must be tailored to the underlying etiology, balancing the reduction in stroke risk against the hazard of hemorrhage.
No takes yet. Share an insight, caveat, or question.
Etiology-based antithrombotic selection may refine secondary prevention; leaves open the need for etiology-stratified RCTs.
Chong et al. (2005) conducted a review in Stroke prevention. Anticoagulation and platelet antiaggregation therapy was evaluated on Stroke prevention. Choice of antithrombotic therapy depends on stroke etiology, with oral anticoagulation preferred for cardioembolism in atrial fibrillation and antiplatelet therapy favored in other settings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: